Literature DB >> 8080884

Acquired von Willebrand disease as a cause of recurrent mucocutaneous bleeding in primary thrombocythemia: relationship with platelet count.

P J van Genderen1, J J Michiels, S C van der Poel-van de Luytgaarde, H H van Vliet.   

Abstract

We present a 4-year follow-up of a 42-year-old patient with primary thrombocythemia whose clinical course was complicated by two major mucocutaneous bleeding episodes. On both occasions an acquired functional von Willebrand factor deficiency was demonstrated. In contrast to what is reported in the literature, an inverse relationship between platelet number and plasma high-molecular-weight multimers of von Willebrand factor was established.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8080884     DOI: 10.1007/bf01698487

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  15 in total

1.  Letter: A method for assaying von Willebrand factor (ristocetin cofactor).

Authors:  D E Macfarlane; J Stibbe; E P Kirby; M B Zucker; R A Grant; J McPherson
Journal:  Thromb Diath Haemorrh       Date:  1975-09-30

Review 2.  Essential thrombocythemia.

Authors:  A I Schafer
Journal:  Prog Hemost Thromb       Date:  1991

3.  An ELISA test for the binding of von Willebrand antigen to collagen.

Authors:  J E Brown; J O Bosak
Journal:  Thromb Res       Date:  1986-08-01       Impact factor: 3.944

4.  Plasma von Willebrand factor abnormalities in patients with essential thrombocythemia.

Authors:  K Sato
Journal:  Keio J Med       Date:  1988-03

Review 5.  Primary thrombocythemia: diagnosis, clinical manifestations and management.

Authors:  P J van Genderen; J J Michiels
Journal:  Ann Hematol       Date:  1993-08       Impact factor: 3.673

6.  Enzyme immunoassay for factor VIII-related antigen.

Authors:  J Cejka
Journal:  Clin Chem       Date:  1982-06       Impact factor: 8.327

7.  Visualization of von Willebrand factor multimers by enzyme-conjugated secondary antibodies.

Authors:  F Brosstad; I Kjønniksen; B Rønning; H Stormorken
Journal:  Thromb Haemost       Date:  1986-04-30       Impact factor: 5.249

8.  Clinical course of essential thrombocythemia in 147 cases.

Authors:  P Fenaux; M Simon; M T Caulier; J L Lai; J Goudemand; F Bauters
Journal:  Cancer       Date:  1990-08-01       Impact factor: 6.860

9.  Abnormal structure of von Willebrand factor in myeloproliferative syndrome is associated to either thrombotic or bleeding diathesis.

Authors:  M F López-Fernández; C López-Berges; R Martín; A Pardo; F J Ramos; J Batlle
Journal:  Thromb Haemost       Date:  1987-08-04       Impact factor: 5.249

10.  Acquired von Willebrand's disease in the myeloproliferative syndrome.

Authors:  U Budde; G Schaefer; N Mueller; H Egli; J Dent; Z Ruggeri; T Zimmerman
Journal:  Blood       Date:  1984-11       Impact factor: 22.113

View more
  5 in total

Review 1.  What is the standard treatment in essential thrombocythemia.

Authors:  Tiziano Barbui
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

Review 2.  Acquired von Willebrand syndrome: its pathophysiology, laboratory features and management.

Authors:  Hiroshi Mohri
Journal:  J Thromb Thrombolysis       Date:  2003-06       Impact factor: 2.300

Review 3.  Myeloproliferative and thrombotic burden and treatment outcome of thrombocythemia and polycythemia patients.

Authors:  Jan Jacques Michiels
Journal:  World J Crit Care Med       Date:  2015-08-04

Review 4.  New Developments in Diagnosis and Management of Acquired Hemophilia and Acquired von Willebrand Syndrome.

Authors:  Frank W G Leebeek
Journal:  Hemasphere       Date:  2021-06-01

5.  Aortic valve replacement in a young patient with essential thrombocytosis.

Authors:  Kashif Ahmed; Hunaid A Vohra; Alison Milne; Stephen M Langley
Journal:  J Cardiothorac Surg       Date:  2008-01-30       Impact factor: 1.637

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.